 Home > Active Ingredient News > Blood System > The complete remission rate of refractory patients exceeds 30% CD37 targeted ADC combination Phase 2...

The complete remission rate of refractory patients exceeds 30% CD37 targeted ADC combination Phase 2...

 Last Update: 2021-06-22
 Source: Internet
 Author: User

Tags

finasteride drug class

cell membrane definition

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 14, 2021, Debiopharm announced that its CD37-targeted antibody conjugate (ADC) naratuximab emtansine, combined with rituximab (anti-CD20 antibody), is used in the treatment of relapsed/refractory (R/R) diffuse Positive results were obtained in a phase 2 clinical trial of large B-cell lymphoma (DLBCL)

The latest results presented at the European Hematology Association (EHA) annual meeting on June 12 showed that among refractory patients who have previously received more than two treatments, naratuximab emtansine combined with rituximab can be evaluated The objective response rate (ORR) among the patients (N=76) was 44.

In terms of safety, the safety characteristics of the combination therapy are predictable and manageable, the rate of treatment discontinuation due to adverse events is low (8%), and the incidence of severe febrile neutropenia is low (4%)

Naratuximab emtansine is a potentially innovative method for the treatment of patients with B-cell malignancies

Image source: Bioconjugator, CC BY-SA 4.

Note: The original text has been deleted

Reference materials:

[1] Debiopharm's CD37 Antibody Drug Conjugate Shows Promising Phase II Results for the Treatment of B-Cell Malignancies.

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.